{"id":"NCT01521559","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)","officialTitle":"A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2013-08","completion":"2014-03","firstPosted":"2012-01-30","resultsPosted":"2014-11-13","lastUpdate":"2014-11-13"},"enrollment":183,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Branch Retinal Vein Occlusion"],"interventions":[{"type":"PROCEDURE","name":"Macular Laser Photocoagulation","otherNames":[]},{"type":"DRUG","name":"Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)","otherNames":[]}],"arms":[{"label":"Macular Laser Photocoagulation Treatment (Control)","type":"SHAM_COMPARATOR"},{"label":"Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4","type":"EXPERIMENTAL"}],"summary":"This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in patients with macular edema secondary to BRVO.","primaryOutcome":{"measure":"Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF","timeFrame":"Baseline to week 24","effectByArm":[{"arm":"Macular Laser Photocoagulation Treatment (Control)","deltaMin":24,"sd":null},{"arm":"Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)","deltaMin":48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["United States","Canada","Japan"]},"refs":{"pmids":["32633861"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":92},"commonTop":["Conjunctival haemorrhage","Hypertension","Nasopharyngitis","Eye pain","Urinary tract infection"]}}